We are glad to present the five best posters submitted to our poster contest targeting the UNGASS on drugs this year!

In this edition of Dose of Science, we are going to take a look at a meta-analysis of using LSD therapy to treat alcoholism [1]. ‘Meta-analysis’ means that the study pools together data derived from multiple trials and re-analyses the combined evidence. The advantage is that the combined evidence reduces the statistical uncertainties, and permits more robust conclusions than any of the individual studies in isolation.

Drugreporter’s video advocacy team filmed key speeches and interviewed some of the participants at the UN’s drug meeting in Vienna – please watch and share our movie!

A surprise decision from the otherwise super-conservative Polish government: it improves access to cannabis for medical purposes.

While Colombia and the Czech Republic spoke up for drug policy reform at the opening day of the CND, others such as Russia or Thailand prefer the status quo and oppose any changes.

The UNGASS draft document still does not reflect the realities of the war on drugs, but continues to dream about a drug-free society, just like 20 years ago.

The ‘cognitive impairment theory’ proposes that cannabis causes cognitive decline. The hypothesis has gained some support from a 2012 study, but a recent paper with twin participants strongly argued against the theory. Both studies agree on the association between smoking and cognitive decline. Where they disagree is whether the relationship is causal or merely correlation. In this Dose of Science we take a close look at the question. 

Watch Drugreporter’s new video, marking the launch of the Consensus Statement from the International Network of People Who Use Drugs.

The Polish Drug Policy Network organised a conference on urban drug policies in Warsaw, where participants adopted a new declaration which will be promoted at the UN Commission on Narcotic Drugs by the Polish government. Read our report from the conference! 

Norway claims to have a progressive drug policy – but does it really? Our guest author from NORML Norway thinks otherwise.